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Summary
The X-ray crystal structures for the complexes of three
designer antibiotics, compounds 1, 2, and 3, bound to
two models for the ribosomal aminoacyl-tRNA site (A
site) at 2.5–3.0 A˚ resolution and that of neamine at
2.8 A˚ resolution are described. Furthermore, the com-
plex of antibiotic 1 bound to the A site in the entire 30S
ribosomal subunit of Thermus thermophilus is re-
ported at 3.8 A˚ resolution. Molecular dynamics simula-
tions revealed that the designer compounds provide
additional stability to bases A1492 and A1493 in their
extrahelical forms. Snapshots from the simulations
were used for free energy calculations, which revealed
that van der Waals and hydrophobic effects were the
driving forces behind the binding of designer anti-
biotic 3 when compared to the parental neamine.
Introduction
The bacterial ribosome is an important target for antibi-
otics [1]. The recent availability of crystal structures for
the 30S and 50S subunits of the bacterial ribosome and
that of the complete 70s ribosome (reviewed in [2]) has
created the possibility for de novo design of molecules
that bind to the ribosome and disrupt its function. We
recently disclosed a set of antibiotics that were designed
to bind to the ribosomal aminoacyl-tRNA site (A site) [3].
These antibiotics were the outcome of a computational
search of three-dimensional molecules for binding to
the A site and their ultimate chemical syntheses, which
were discussed at length previously [3]. These molecules
were shown to bind to a model of the A site in solution,
and, in one case, we recently reported a brief communi-
cation of the X-ray structure for the complex of the A site
model and the antibiotic [4].
Three of these designer antibiotics are compounds 1,
2, and 3 (Figure 1A), which are the subjects of this report.
We disclose herein a set of biochemical analyses with
these antibiotics that reveal the various nuances of their
properties. Furthermore, X-ray structures for these mol-
ecules with the model of the A site, along with one with
the 30S ribosomal subunit, reveal the binding modes of
the antibiotics at the target site. In addition, molecular
*Correspondence: j.murray@vernalis.com (J.B.M.); mobashery@nd.
edu (S.M.)dynamics simulations were carried out on two of these
complexes, and snapshots were used to carry out free
energy calculations for the binding of neamine and anti-
biotic 3 to the A site. Valuable insight into the driving
forces behind the binding of these antibiotics was ar-
rived at as the van der Waals, electrostatics, hydropho-
bic, and entropic components of the free energy of bind-
ing are determined individually. Analyses also shed light
on the differences in molecular dynamics experienced
by the surrounding RNA bases in the presence of two
of these antibiotics. It appears that the two arms incorpo-
rated into the designer antibiotics serve as electrostatic
anchors, which are the structural reasons for additional
stability of bases A1492 and A1493 that adopt an extra-
helical conformation. The simulations also reveal that
these bases are highly flexible in solution, and that they
sample a wide variety of conformations.
Results and Discussion
We had presented data on the broad spectrum of the an-
tibacterial activity that compounds 1–3 exhibited in the
original disclosure of these antibiotics [3]. Also, we had
shown by a fluorescence analysis that these antibiotics
bind to a model of the bacterial ribosomal A site. We
report, herein, the X-ray structure of antibiotic 1 bound
to the A site in the 30S subunit of the ribosome of Ther-
mus thermophilus at 3.8 A˚ (data processing and refine-
ment statistics are presented in Table 1 for this and all
other structures reported in this work). Furthermore,
we report the structures of 1, 2, and 3 and that of the
neamine core bound to a model A site RNA construct.
These structures range from 2.5 to 3.0 A˚ resolution and
reveal in detail the molecular interactions made by these
antibiotics. We will use the Escherichia coli numbering
scheme throughout in describing the structure.
The A site model constructs contain two identical A
site motifs, separated by four GC base pairs, each of
which closely duplicates the three-dimensional structure
of the A site in the ribosome. As an aid to optimize the
crystallization conditions, we have used two constructs
that differ only by the overhanging residues, UU (con-
struct 1) and C (construct 2) (Figure 1B). The best diffract-
ing crystals were obtained by using construct 1 for anti-
biotic 1 and neamine, and construct 2 for antibiotics
2 and 3. Two distinct crystal-packing arrangements
were observed (Figure 1B). Type 1 was obtained for anti-
biotic 1 and is similar to those previously reported [5].
The remaining three antibiotics exhibit a new crystal-
packing arrangement (Type 2). For both packing ar-
rangements, only one of the sites contains an antibiotic
with the empty sites involved in crystal-packing interac-
tions that prevent its occupation by the antibiotic.
The crystal packing around the binding site for antibi-
otic 1 (Type 1) is similar to those reported previously [5].
Briefly, A1492 and 1493 adopt an extrahelical conforma-
tion packing in the minor groove of a neighboring mole-
cule. The empty site is less well ordered. The adenine
bases of A1492 and A1493 are completely disordered,
with only weak density present for the ribose moieties.
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130Figure 1. Antibiotic Structures and Crystal
Packing Interactions for Model A Site
(A) A schematic of compounds 1–3.
(B) Illustration of the two packing types ob-
served; Type 1 with construct 1, and Type 2
with either construct 1 or 2. Red residues rep-
resent base pairing from symmetry mates.
Gold residues are largely disordered, and
blue residues are the well-ordered extra-heli-
cal elements making crystal contacts. The
box represents the site of antibiotic binding.
(C)The interactionofU1402 (slate) from asym-
metry mate with A1408 (salmon) in the empty
site for packing Type 1. The electron density
is only shown for U1402, contoured at 1s
(2Fo2 Fc).
(D) The interaction of U1406 (yellow) with
a symmetry mate, A1408 (green), to form an
AU base pair, and, A1492 (green) from the
same symmetry mate forming the Hoogsteen
AU base pair with U1495 (yellow) for pack-
ing Type 2. The electron density is only
shown for U1406 and A1408, contoured at
1s (2Fo 2 Fc).The electron-rich phosphates of A1492 and A1493 can
be located, but, again, the density is only present at
much lower contour levels than in the core of the struc-
ture. This may reflect the lack of order present in the A
site, until mRNA or an antibiotic is bound, as has been
observed in the structures of unliganded 30S subunits
[6]. An interesting feature in this structure is the crystal
contact made by U1402 (the first overhanging U,Figure 1B, construct 1, Type 1) extending into aneighbor-
ing empty site and making a UA base pair with A1408.
The density for this residue does not define the orienta-
tion of the residue unambiguously, but it is clear and re-
turns after generation of a simulated annealing omit map
for this residue. Attempts to refine either of the disor-
dered A1492 or A1493 residues into this density proved
less than satisfactory; thus, the most reasonable
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131Table 1. Data Processing Statistics and Refinement Statistics
Antibiotic 1 Antibiotic 1-30S Antibiotic 2 Antibiotic 3 Neamine
Space group P21 P41212 P212121 P212121 P212121
Cell parameters a = 46.52 A˚;
b = 32.97 A˚;
c = 46.00 A˚;
90, 95.62, 90
a = 403.32 A˚;
b = 403.32 A˚;
c = 176.69 A˚
a = 33.052 A˚;
b = 46.461 A˚;
c = 89.524 A˚
a = 32.80 A˚;
b = 46.55 A˚;
c = 88.81 A˚
a = 33.055 A˚;
b = 47.31 A˚;
c = 85.34 A˚
Outer shell 3.11–3.0 A˚ 3.93–3.80 A˚ 2.69–2.60 A˚ 2.59–2.50 A˚ 2.93–2.80 A˚
Unique reflections 2,795 138,452 4,451 4,719 3,221
Completeness (%) 97.7 (100) 97.4 (96.2) 97.6 (97.6) 94.2 (98.2) 89.7 (85.8)
Redundancy 3.6 3.1 3.1 6.1 4.7
Rmerge (%)
a 7.8 (20.6) 16.1 (68.0) 9.2 (42.3) 6.6 (39.4) 7.9 (32.7)
I/s(I) 8.0 (3.2) 8.2 (1.9) 5.8 (1.6) 16.0 (3.5) 8.1 (2.3)
Reflections 2,515 (work set);
280 (test set)
131,434 (work set);
6,940 (test set)
3,845 (work set);
445 (test set)
4,242 (work set);
477 (test set)
2,916 (work set);
305 (test set)
Resolution range 15.0–3.0 A˚ 30.0–3.8 A˚ 30.0–2.6 A˚ 30.0–2.5 A˚ 30.0–2.8 A˚
RNA atoms 932 32,391 892 892 900
Ligand atoms 34 34 35 36 21
Protein atoms — 19,078 — — —
Solvent atoms 0 0 31 62 13
Metallic atoms — 114 — —
R factor workb 21.1% 25.9% 25.00% 24.6% 22.5%
Rfree 26.7% 31.5% 29.89% 29.8% 24.9%
Average B factor 80.2 A˚2 84.9 A˚2 55.6 A˚2 46.9 A˚2 59.9 A˚2
Rmsd bond lengths 0.006 A˚ 0.019 A˚ 0.015 A˚ 0.006 A˚ 0.004 A˚
Rmsd bond angles 0.99º 1.64º 1.97º 1.05º 0.92º
Average radial error
<u>c
0.45 A˚ 0.56 A˚ 0.46 A˚ 0.42 A˚ 0.47 A˚
a Rmerge =S jI (k)2 <I>j/S I (k), where I (k) is the value of the kth measurement of the intensity of a reflection, <I> is the mean value of the intensity of
that reflection, and the summation is over all measurements. The values in parentheses refer to the highest-resolution shells.
b R factor = S hkl jFo (hkl) 2 Fc (hkl)j/S hkl Fo (hkl).
c Average radial error, <u>, of coordinates derived from the Luzzati plot as implemented in sfcheck, part of the CCP4 suite of programs [7].explanation is the crystal-packing interaction described
(Figure 1C).
A feature of Type 2 crystal packing is the displace-
ment of U1406 from its UU base pair to an extrahelical
conformation and the formation of an AU Hoogsteen
base pair when A1492 from the empty site of a neighbor-
ing molecule replaces U1406 (Figure 1D). Furthermore,
the displaced U1406 stacks upon A1491 of the empty
site and forms a weak base pair in the empty site with
A1408, thus mimicking a Type 1 crystal-packing interac-
tion. A1492 and 1493 adopt an extrahelical conformation
and make a number of minor groove contacts with
a neighboring molecule.
The crystal structure of antibiotic 1 in the 30S subunit
represents the first structure of a designer antibiotic
bound to its natural ribosomal target and confirms our
observations when the model A site RNA constructs
are used. Even though the resolution for this structure
is relatively low, it shows clearly the orientation of the an-
tibiotic with density extending partially along arms #1
and #2 (Figure 2A). Furthermore, the two codon-antico-
don-sensing adenosines A1492and A1493have adopted
an extrahelical conformation similar to that observed in
all model A site-aminogylcoside structures. This is con-
sistent with the structures determined by Ramakrishnan
and coworkers of paromomycin in the 30S subunit [7];
this group’s subsequent work has shed light on the
mechanism of action by A site binding antibiotics [2]. In
the apo 30S structures, A1492 and A1493 are not ob-
served in an extrahelical conformation. It is also notable
that we could not identify any electron density consis-
tent with alternative binding sites in the 30S subunit forantibiotic 1, thus indicating that these compounds are
specific for the A site.
Comparison of the two structures for antibiotic 1 (in
the 30S subunit and in the model A site RNA construct)
shows that the structures are the same, validating the
use of the A site model. The rmsd between the two struc-
tures when using common residues (U1404 to C1409 and
G1491 to U1497) is 1.1 A˚ (0.84 A˚ for main chain, ribose,
and phosphate). The superposition of the two structures
is shown in Figure 2B.
The 2.5 A˚ crystal structure of the A site RNA construct
in complex with antibiotic 3 unambiguously defines the
precise location for all atoms of antibiotic within the A
site, as previously communicated [4]. The structure of
antibiotic 2 within the A site revealed that the last two
atoms of arm #2 are not well defined by the electron den-
sity. Antibiotic 1 has the neamine core and arm #1 (sub-
stitution at N1 of neamine) in the same positions as those
of antibiotics 2 and 3. The shorter arm #2 of antibiotic
1 (substitution at O6 neamine) does not point down the
major groove, but, rather, it continues orthogonal to
the helical axis. This allows the terminal amine to make
hydrogen bonds with the phosphates of C1404 and
G1405 at 3.0 and 3.2 A˚, respectively. Furthermore, the
displaced U1406 stacks upon A1491 and forms a weak
base pair in the empty site with A1408, thus mimicking
a Type 1 packing interaction.
Neamine is representative of a moiety present in many
aminoglycosides that bind to the A site, and it is the core
structure on which we have based our design efforts. To
ensure that the binding of this core is not different than
that observed in larger aminoglycosides, we have
Chemistry & Biology
132Figure 2. Structure of Antibiotic 1 Bound to
the 30S Subunit and Model A Site Antibiotic
Structures
(A) Top. The cartoon shows the full structure
of the 30S subunit; the RNA chain is shown
in gold, and protein chains are shown in yel-
low. The liganded A site is highlighted in
blue. Bottom. Stereoview of antibiotic 1
(green) and the displaced A1492 and A1493
(cyan) in the 30S subunit. The electron den-
sity shown is the difference density (Fo 2 Fc)
contoured at 3.5 s. The antibiotic and bases
A1492 and A1493 were omitted from the
phasing model. This unambiguously reveals
the orientation of antibiotic 1, which is entirely
consistent with that observed in the model A
site construct. This also shows that A1492 is
less well defined than A1493.
(B) Superposition of the binding sites for anti-
biotic 1 from 30S (cyan) and the A site con-
struct (salmon). The binding mode is essen-
tially identical, and the largest difference is
seen in the orientation of the base of A1492,
which, as noted above, is the least well de-
fined part of the binding site in the 30S sub-
unit.
(C) A superposition of all four structures. The
color scheme is as follows; antibiotic 1, 2,
and 3 and the neamine core are colored
salmon, purple, blue, and yellow, respec-
tively. The superposition was calculated
from all atoms by using residues 1407–1410
and 1490–1495. This figure also illustrates
the flipping out of U1406 for packing Type 2.solved the structure of neamine in the A site at 2.8 A˚. The
neamine core alone binds in the same manner as that
observed in the other structures reported. With residues
1407–1410 and 1490–1495, the rmsd between the struc-
tures for antibiotic 1, 2, and 3, and the neamine core are
0.26, 0.39, and 0.31, respectively. This is illustrated in
Figure 2C. In light of the fact that the neamine core is de-void of antibacterial activity, it is the two arms of antibi-
otics 1–3 that are responsible for the dramatic antibacte-
rial activity. It is worth mentioning that the arms might
also be important in the uptake of the antibiotics by bac-
teria.
The aminohydroxybutyryl group that forms arm #1 has
the same structure in the three complexes (1–3) with the
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133Table 2. Free Energy of Binding for the Formation of the Complexes between A Site and Compound 3 or Neamine
DEvdW DGelec DGsurf TDS DGcalc DGexp
Compound 3 235.0 6 0.9 213.5 6 0.6 24.8 6 0.1 245.6 6 1.2 27.7 6 1.6 27.4
Neamine 220.0 6 0.6 215.0 6 0.3 23.4 6 0.1 231.6 6 1.2 26.8 6 1.4 26.5
All energies are given in kcal/mol. DEvdW, van der Waals potential energy; DGelec, electrostatic energy and electrostatic contribution to the
solvation free energy; DGsurf, nonpolar contributions to solvation free energy; DS, entropy; DGcalc, change in the calculated free energy of bind-
ing; DGexp, change in the experimentally determined free energy of binding calculated from the dissociation constants.A site RNA model. The arm makes four contacts with the
RNA. These interactions are dominated by involvement
of the terminal amino group, which contacts the bases
of G1403, G1498 (via water), and C1497. The hydroxyl
group makes a water-mediated contact to the phos-
phate backbone of U1495.
Arm #2 adopts different conformations in each of the
three antibiotics. For arm #2 of antibiotics 2 and 3, the
secondary amine makes a hydrogen bond with the N7
of G1405. Antibiotic 1 does not make this hydrogen
bond with N7 of G1405, but it has the NH rotated 90º
down the helix. This rotation allows the terminal amine
to make the more favored electrostatic interactions de-
scribed below. Antibiotic 3 has the methylene hydro-
gens spaced between the phosphate backbone of resi-
dues C1404, G1405, and U1406. The terminal amino
group also makes electrostatic interactions with the
phosphate groups of G1405 and U1406. The lower reso-
lution for the structure of antibiotic 2 makes definitive
conclusions about the orientation of this flexible arm dif-
ficult; however, refinement of the structure leaves the C1
and C2 positions of the aliphatic portion of arm #2 ro-
tated by approximately 110º toward the RNA. This al-
lows the less well-ordered atoms to adopt a conforma-
tion that is similar to that of antibiotic 3.
Molecular dynamics simulations provide coordinates
and momenta of atoms with respect to time, and they
thus enable us to make a detailed study of the various
conformations sampled by a system. Furthermore, mo-
lecular dynamics simulation between complexes of pro-
teins and nucleic acids and small molecules could be
used to determine the free energy of binding of these
molecules to their binding sites; one such method is
known as MM-PBSA [8], which combines polar and non-
polar contributions to the solvation free energy, energies
from electrostatic and van der Waals interactions, and
entropy calculations. This method has been extensively
used for protein-ligand complexes, and, less commonly,
it has been used for nucleic acid-ligand complexes.
Here, the MM-PBSA method is used for the first time to
probe the binding of aminoglycoside derivatives to the
A site of the ribosome. Two separate molecular dynam-
ics simulations were carried out; one for neamine and
another for antibiotic 3, each bound to the A site RNA
model (by using construct 2 [Type 2], see Figure 1B).
The computed binding free energy and its compo-
nents are listed in Table 2 for neamine and antibiotic 3, re-
spectively. The binding free energies (DGcalc) are in good
agreement with experiment (DGexp), and they also repro-
duce the experimental observation showing neamine
with a larger dissociation constant. Comparison of the
individual components listed in Table 2 reveal that van
der Waals interactions (DEvdW) provide significant stabi-
lization to antibiotic 3 and neamine. However, it appearsthat these effects play a more important role in the bind-
ing of antibiotic 3 by 15 kcal/mol. This is likely due to the
high degree of complementarity between the arms of the
designer compound (not present in neamine) and the A
site pockets they were intended to target. The electro-
static contributions to free energy of binding (DGelec),
which combine the electrostatic interactions and the sol-
vation free energy determined by Poisson-Boltzmann
electrostatics, also provide additional stability to the for-
mation of the complex between these compounds and
the A site. However, the role of electrostatics appears
to be more significant, by approximately 1.5 kcal/mol,
in the case of binding of neamine as opposed to antibi-
otic 3 (this despite the hydrogen bonding interactions
between the arms of antibiotic 3—not present in
neamine—and the receptor site). This result is likely
due to the penalty incurred for desolvating antibiotic 3,
as the additional charged amino groups in the arms of
antibiotic 3 likely form highly favorable interactions
with the solvent. The favorable hydrogen bonding inter-
actions between compound 3 and the receptor site are
not sufficient to offset this desolvation penalty. Further-
more, the hydrophobic component of the solvation free
energy (DGsurf) is more favorable, by 1.4 kcal/mol, for
antibiotic 3, likely as a result of the aliphatic groups in
the arms of antibiotic 3, which prefer the binding pocket
of the A site that is partly shielded from water. Finally,
entropy (DS) appears to play a destabilizing role for the
binding of antibiotic 3 and of neamine. However,
a more significant penalty is incurred in the case of anti-
biotic 3, as the arms of this compound introduce a larger
degree of disorder in the solvent (not present in
neamine), which will be lost due to binding to the A site.
The larger degree of stabilization required to bind antibi-
otic 3 to the A site pocket will lead to a larger entropy
cost. It thus appears that van der Waals interactions
and the hydrophobic component of the solvation free
energy of binding are the main driving forces behind
the binding of the designer antibiotics over neamine.
This is due to a high degree of complementarity between
the arms of the designer antibiotic, which fit well into the
receptor subsites they were designed to exploit.
To study the degree of flexibility exhibited by these
systems, base-averaged fluctuations were determined
from snapshots collected at 0.2 ps intervals during the
course of the 1.8 ns trajectories, as shown in Figure 3A.
The peaks around bases C1498, G1403, G1414, and
C1486 are typical of terminal bases, which exhibit more
flexibility, due to the fact that they form only one-sided
stacking interactions while being fully exposed to sol-
vent on the other side. Another peak in the fluctuation
of U1406 is consistent with the fact that this base has
an extrahelical conformation and could freely undergo
motion in the solvent. The region between A1492 and
Chemistry & Biology
134Figure 3. Dynamics of Bases in the Presence of Neamine and of
Antibiotic 3
(A) Base-averaged fluctuation of bases from the molecular dynam-
ics simulations of neamine (closed circles) and antibiotic 3 (open
circles), each bound to the A site model.
(B–D) (B) Definition of pseudo dihedral angles c1 and c2. Distribu-
tion of the pseudo dihedral angles c1 and c2, as defined in (B),
from the molecular dynamics simulation for c1 (see [C]) and c2
(see [D]) in complex with the A site model. Values for neamine are
shaded.A1493, which shows larger flexibility in the neamine sim-
ulations, is of interest, given the important role that has
been attributed to these bases in the process of transla-
tion. A peak in the fluctuation at positions A1492 and
A1493 is due to the extrahelical conformations adopted
by these bases, leading to more significant motion due
to the lack of base pairing and stacking interactions.
However, it is interesting to note that the fluctuations ex-
perienced by A1493 in the neamine complex were larger
than those experienced by A1493 in the complex with
antibiotic 3, with a difference of 0.7 A˚2.
The motion of bases A1492 and A1493 from the intra-
helical to extrahelical positions in the A site would appear
to be significant in the translation process [9, 10]. An im-
portant outcome in translation is the high fidelity of the
transmission of the sequence information from mRNA
to the nascent protein sequence during the events of mo-
lecular recognition between codon and anticodon of
mRNA and tRNA, respectively. Ramakrishnan recently
documented that in the ternary complex of the 30S ribo-
somal subunit with fragments of RNA involved in the co-
don-anticodon recognition events, the A1492 and A1493
were trapped in the extrahelical positions, such that the
bases were interacting with the codon-anticodon enti-
ties [9]. The authors argued that these extrahelical inter-
actions played a key role in discrimination against bind-
ing by noncognate or near-cognate tRNA molecules,
proposed also by Yoshizawa and coworkers [10]. It is
known that binding of aminoglycoside antibiotics at the
ribosomal A site increases the rate of misincorporation
of amino acids during translation, which ultimately leads
to the demise of bacteria [11]. In light of the fact that the
same extrahelical positions for A1492 and A1493 have
been seen when aminoglycosides bind the A site [7,
12], the point was made that, in the presence of amino-
glycosides, the higher rate of amino acid misincorpora-
tion takes place because near-cognate or noncognate
tRNA molecules are increasingly recognized as cognate
tRNA, hence contributing to high error rates. The confor-
mational change experienced by A1492 and A1493 in the
presence of aminoglycosides was further corroborated
by fluorescence labeling experiments carried out in the
Pilch [13, 14] and Hermann [12] laboratories that re-
vealed that ligand binding to the A site induces confor-
mational change at A1492 and A1493.
Given the importance in the proposed role that A1492
and A1493 play in the decoding process, further com-
parison of the flexibility of these bases in the presence
of neamine and of antibiotic 3 was made. To quantify
the degree of extrahelical conformational change that
these bases undergo, pseudodihedral angles, akin to
those recently used in a DNA simulation [15], were de-
fined, as shown in the inset of Figure 3B. These angles
were defined by using bases G1491/A1492 (c1) and ba-
ses A1493/G1494 (c2). To put these angles in perspec-
tive, c1 and c2 are determined from the recently solved
X-ray structure of the 30S ribosome with no antibiotic
bound to the A site [6] with fully stacked intrahelical
A1492 and A1493, and from the X-ray structure of the
30S ribosome with antibiotic 1 bound to the A site de-
picting the extrahelical bases; these angles were found
to be 5º and 29º when the bases are fully stacked intra-
helically, and 2135º and 2256º for the extrahelical con-
formations. The distributions of c1 and c2 are shown in
Antibiotics and Ribosomal Aminocyl-tRNA
135Figures 3C and 3D. When antibiotic 3 is bound to the A
site, c1 ranges from 260 to 2175, compared with 244
to 2147 when neamine is bound. The distribution of c1
angles, however, is narrower in the case of antibiotic 3,
as reflected by a full width at half-maximum of 30º, as
opposed to 60º for neamine. The majority of the c1 an-
gles adopted by A1492 when antibiotic 3 is bound are
within 20º of 2120, the mean value. When neamine is
bound, the distribution of c1 values is more uniform.
The distributions of c2, as shown in Figure 3D, indicate
a similar trend, but there appears to be much less over-
lap in the distributions. The full width at half-maximum
for antibiotic 3 is 20º, compared to 60º for the neamine
complex. The distributions of c1 and c2 angles reflect
the differences between the motions experienced by
A1492 and A1493 in the presence of neamine or of anti-
biotic 3. It appears that antibiotic 3 has a stabilizing ef-
fect on the bases, favoring the extrahelical conformers.
In the presence of neamine in the A site, A1492 and
A1493 seem to prefer conformations of the bases that
are closer to the stacked intrahelical positions, while
also exhibiting equal probabilities of adopting extraheli-
cal conformations, as evidenced by the more uniform
and broad distributions of c1.
To illustrate the differences in the conformational
changes that A1492 and A1493 experience in the pres-
ence of neamine and of antibiotic 3 in the complexes,
snapshots were collected at 100 ps intervals along the
1.8 ns dynamics trajectory, as shown in Figure 4. In the
X-ray structure of the A site RNA model, U1406 is shown
to adopt an extrahelical conformation due to interac-
tions between neighboring RNA molecules in the crystal
lattice. One interesting aspect of the dynamics simula-
tion with antibiotic 3 is the fact that U1406 is found to
move gradually into the minor groove and finally adopt
its native intrahelically stacked conformation, culminat-
ing in the hydrogen bond formation between O4 of
U1406 and N3 of U1495. At the beginning of the trajec-
tory, the O4-N3 distance was 14 A˚. The distance gradu-
ally decreases during the first 200 ps of the simulation,
reaching an average value of 2.7 A˚ over the remaining
1.6 ns of simulation. Figure 4 also illustrates that A1492
and A1493 experience more flexibility when neamine is
bound. In contrast, the bases appear to be stabilized in
an extrahelical position by the presence of antibiotic 3
in the A site. The differences between the structures of
the neamine core and of antibiotic 3 center on the two
arms, which provide the stabilizing effect for the com-
plex of 3 bound at the A site. The two arms serve as elec-
trostatic anchors by the formation of hydrogen bonds
with the A site RNA. These anchors provide additional
stability to the extrahelical conformation of bases
A1492 and A1493. This added stability is likely the basis
for the potent antimicrobial activity of compound 3 in
light of a recent study showing that the antimicrobial
activity of paromomycin is rooted in its ability to lead
to destacking of these bases [13, 14].
We have also carried out a series of functional and
binding analyses. These results are summarized in Table
3. While there is some correlation between the binding
data and translation inhibition, this is not absolute and
does not hold up for the parental molecule neamine of
these series, which is a weak A site binder (Kd = 19 mM)
[3], but a potent inhibitor of bacterial translation(IC50 = 0.13 mM; see Table 3). The likely explanation for
this is that these compounds are transported into the cy-
toplasm in an energy-driven process that could proceed
against a concentration gradient. A site binding was as-
sayed in an alternative fluorescence assay by using a
fluorescently labeled A site RNA and paromamine, and
the decrease in fluorescence resonance energy transfer
(FRET) upon competition of a test compound at 500 mM
was measured [16]. In this assay, all compounds (1–3),
including amikacin, were active, whereas neamine
showed less than 50% inhibition, which correlates with
its comparably weak antibacterial activity. Antibiotics
1–3 have similar affinities for the A site RNA, and all
show similar antibacterial activities and no cytotoxicity
(at >100 mM). Antibiotic 1 is the poorer of the three anti-
biotics in bacterial susceptibility testing [3]. It is also
a weaker inhibitor of in vitro translation, it does not in-
hibit translation in the more stringent MS2 bacterial
translation assay, and it lacks selectivity for bacterial
over mammalian translation. Antibiotics 2 and 3 do
show selectivity in the in vitro translation assays. Fur-
thermore, since they are nontoxic to the HeLa cells at
concentrations above 100 mM, it would appear that
they do not readily penetrate the mammalian cells to
manifest any potential inhibition of the translation ma-
chinery. The results of the stringent MS2 activity assay
are interesting in light of the fact that antibiotics 2 and
3 would appear to be superior to amikacin (which shows
Figure 4. Illustration of Base Motion in the Presence of Neamine
and of Antibiotic 3
Superimposition of snapshots collected along the 1.8 ns molecular
dynamics simulation at 200 ps intervals of (A) antibiotic 3, with
green and orange arrows pointing to arms #1 and #2 of the antibi-
otic, respectively, and (B) neamine bound to the A site model.
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Antibiotic A Site Kd
a E. coli IVT IC50 RRL IVT IC50 SI MS2 Activity MIC CC50
1 2.2 6 0.1 38 6 2 17 6 0.3 0.4 — 0.8 >100
2 5.9 6 1.3 3 6 2 30 6 2 10 +++ 0.8 >100
3 3.9 6 0.1 4 6 3 23 6 3 6 +++ 0.8 >100
Neamine 19 6 1 0.13 6 0.04 55 6 3 423 +++ 12.5 >100
Amikacin n.d. 0.013 6 0.001 >50 >3846 ++ 3 >100
With the exception of the values for the selectivity index (SI) and the MS2 activity, which are unitless, all other numbers are expressed in mM. SI is
the selectivity index for E. coli IVT IC50 versus RRL IVT IC50.
a A site Kd from [3].>50% inhibition at 200 mM), a clinically used aminoglyco-
side antibiotic. We state parenthetically that antibiotics
1–3 did not inhibit DNA replication and transcription,
indicating that their antibacterial activity is due to inhibi-
tion of translation.
Significance
The three-dimensional structures of a set of three de-
signer antibiotics and their core structural compo-
nents (neamine) have been disclosed. Furthermore,
for the first time, the crystal structure of a designer an-
tibiotic (antibiotic 1) bound to the decoding site of the
30S subunit of the ribosome has also been reported
herein. These structures reveal that the A site bases
A1492 and A1493 undergo a conformational change
upon binding of the designer antibiotics similar to
those of other A site binding antibiotics and also to
the events during the translation process. The arms in-
corporated synthetically to the antibiotics are respon-
sible for their antimicrobial activity, a finding that has
important implication for the future design of novel
antibiotics targeting the A site. Extensive molecular
dynamics simulations, starting with the X-ray struc-
tures of neamine and antibiotic 3 bound to the A site,
revealed that the dynamics experienced by the A1492
and A1493 bases are distinct, with the designer antibi-
otic found to introduce additional stability to the RNA
bases. Additional molecular dynamics-based free en-
ergy calculation revealed that van der Waals and
hydrophobic components are the main driving forces
behind the binding of the compounds to the A site.
Experimental Procedures
Antibiotics 1–3 were synthesized by the reported procedures [3].
Crystallization, Data Collection, and Processing and Structure
Refinement
Crystallization of the 30S subunit [17] and the model A site construct
[4] was performed as previously described. Data were collected at
ESRF on ID29 for antibiotic 1 complexed with the 30S subunit. We
included demeoxycycline at the same concentrations during the
30S soaking experiments as an internal standard; we observed
good ligand density at similar contour levels to antibiotic 1. The
model A site data were also collected at ESRF on ID29 for neamine
and antibiotics 1 and 3; data for the complex with antibiotic 2 were
collected by using a rotating anode RU 300 coupled with an RAXIS
IV++ area detector. The data were processed and scaled with the
HKL2000 suite [18]. With the model A site construct, molecular re-
placement solutions were found by using Molrep [19] with the struc-
ture of Vicens and Westhof [5] (PDB ID 1J7T) or the structure of the
complex of antibiotic 3 (PDB ID 1O9M) [4] as the search model. The30S subunit structure was refined with Refmac5 [19] with the unli-
ganded 30S structure as the starting model (PDB code 1J5E),
whereas the model A site structures were refined with CNX [20].
Where required, the models and ligands were manually built with
O (Table 1) [21].
Functional and Binding Assays
In vitro translation (IVT) assays were essentially performed as de-
scribed earlier [22]. Bacterial translation was measured in a microti-
terplate-based coupled transcription/translation assay by using
E. coli S30 extracts [23] and by using firefly luciferase DNA
(Promega) as a template for transcription/translation. Translation
is quantified by luminescence generated by the luciferase reaction.
Inhibition constants (IC50) were obtained from concentration-
response curves as the concentration of half-maximal inhibition of
coupled transcription/translation. An additional, more stringent
translation assay was performed by using an E. coli S30 extract,
by using MS2 bacteriophage mRNA (Roche) as a template, and by
measuring the incorporation of [3H]methionine into peptide. High
activity (+++) is defined as >75% inhibition, intermediate activity is
defined as >50% inhibition, and inactive compounds as are identi-
fied by <25% inhibition at 200 mM of antibiotic concentration.
Potential inhibition of mammalian translation (‘‘RRL IVT’’ for rabbit
reticulocyte lysate in vitro translation) [24] is measured in an assay
by using rabbit reticulocyte lysate (Promega) and the luciferase
mRNA as a template for translation. As in the bacterial IVT assay,
translation is quantified via luminescence generated by the lucifer-
ase reaction. Cytotoxicity (CC50) is assessed by a dye reduction
assay (CellTiter 96, Promega) with a HeLa cell line.
Antibacterial activity was determined by the microdilution broth
method for the determination of minimum inhibitory concentration
(MIC) as described [3]; Mueller-Hinton broth and Staphylococcus
aureus ATCC 29213 were used as test organisms. MICs were de-
fined as the lowest compound concentrations at which no visible
growth occurred. An influence of the compounds on bacterial tran-
scription and replication was excluded by pulse-labeling experi-
ments: bacterial cells (Staphylococcus aureus ATCC 29213, 98 ml)
were incubated in the presence of tested compound (2 ml) at a con-
centration corresponding to 43 the MIC value, and radioactively la-
beled [3H]thymidine and [3H]uridine (0.5 mCi/ml) were used as pre-
cursors for replication and transcription, respectively. The reaction
was stopped 5 min after addition of the radioactive precursors by
TCA precipitation on glass fiber filters. None of the compounds
interfered with either transcription or translation.
Potential inhibition of mammalian translation (RRL IVT IC50; ‘‘RRL
IVT’’ for rabbit reticulocyte lysate in vitro translation) [24] is mea-
sured in an assay with rabbit reticulocyte lysate (Promega) and the
luciferase mRNA as a template for translation. As in the bacterial
IVT assay, translation is quantified via luminescence generated by
the luciferase reaction. In the MS2 translation assay (Promega), in-
corporation of radioactive amino acid into polypeptide is measured
by using E. coli extracts and by using MS2 phage RNA as a 13 mRNA
template. This assay is generally more stringent than the E. coli IVT
assay, and weak translation inhibitors show no activity. High activity
(+++) is defined as >75% inhibition, intermediate activity is defined
as >50% inhibition, and inactive compounds are identified by
<25% inhibition at 200 mM antibiotic concentration. Cytotoxicity
Antibiotics and Ribosomal Aminocyl-tRNA
137(CC50) is assessed by a dye reduction assay (CellTiter 96, Promega)
with a HeLa cell line.
Computational Procedure
The X-ray structures of the complexes of the A site model with
neamine and with antibiotic 3 provided the initial coordinates for
the molecular dynamics simulations. The following protocol for set-
ting up and running the molecular dynamics simulations applies to
all two cases. Hydrogen atoms were added to the nucleic acid by
using the ‘‘Protonate’’ program, which is part of the AMBER 7 [25]
suite of programs. The AMBER force field parameters were assigned
to all atoms by using the ‘‘parm99’’ set of parameters. The Sybyl 6.9
program (Tripos Inc., St. Louis, MO) was used for the manipulation
and visualization of all structures and for protonation of the bound
ligand. The atomic charges of the antibiotics were determined by us-
ing the RESP methodology [26]. This consisted of first optimizing the
molecules at the HF/6-31G*, followed by a single-point energy cal-
culation to determine the electrostatic potential around the mole-
cule, which was subsequently used in the two-stage RESP fitting
procedure. The Gaussian 98 package [27] was used to carry out all
ab initio calculations. The program Leap was used to neutralize
the complexes, and a total of 18 Na+ ions were added to the RNA
in complex with antibiotic 3, while 20 Na+ ions were added to the
RNA-neamine complex. The complexes were immersed in a box of
TIP3P [28] water molecules such that no atom in the complex was
within 12 A˚ from any side of the box. All bonds involving hydrogen
atoms were constrained by using the SHAKE [29] algorithm, and
a 2 fs time step was used. The particle mesh Ewald [30] method
was used to treat long-range electrostatics. Water molecules were
first energy minimized and equilibrated by running a short simulation
with the complex fixed by using Cartesian restraints. This was fol-
lowed by a series of energy minimizations in which the Cartesian
restraints were gradually relaxed from 500 kcal/A˚2 to 0 kcal/A˚2,
and the system was subsequently slowly heated to 300 K via
a 300 ps molecular dynamics run. Another 400 ps simulation was
carried out at 300 K for further equilibration. This was followed by
a 1.8 ns molecular dynamics simulation at constant pressure and
temperature.
The method for determining the binding free energy has been de-
scribed in the past [8, 31, 32]. It combines molecular mechanics,
Poisson-Boltzmann electrostatics, surface-accessible calculations,
and normal mode analyses for the entropy. These are carried out on
a series of snapshots collected from a molecular dynamics simula-
tion. The binding free energy is expressed as:
DGbind =DG
E
solv +DG
L
solv2DG
EL
solv2DGMM; (1)
where DGbind is the binding free energy, DGMM is the free energy of
association of the enzyme and ligand in the gas phase, and DGEsolv,
DGLsolv, and DG
EL
solv correspond to the solvation free energies of the
A site (E), neamine or compound 3 (L), and the A site-ligand complex
(EL), respectively. DGMM is given by:
DGMM =DEMM2TDS; (2)
where DEMM is the difference in the sum of bond, angle, dihedral,
electrostatic, and van der Waals energies between products and
reactants computed with the AMBER force field. The solvation free
energy is composed of two terms, namely, electrostatics and non-
polar and is given by:
DGsolv =DGPB +DGnonpolar : (3)
In this work, 50 snapshots were collected from the aforemen-
tioned molecular dynamics simulations of antibiotic 3 and neamine
bound to the A site. The electrostatic contribution to the solvation
free energy is determined by using the Delphi II software package
[33] that numerically solves the Poisson-Boltzmann equations to de-
termine the electrostatic contribution to the solvation free energy. A
0.5 A˚ grid size was used, and the dielectric constant for the solute
and solvent were set to 4 and 80, respectively. Atomic radii were
taken from the PARSE parameter set, and partial charges were taken
from Cornell et al. [34] for standard residues; AM1-BCC charges
were assigned to neamine and antibiotic 3. The nonpolar contribu-
tion to the solvation free energy was calculated by using the Molsurfprogram, which is part of the AMBER 8 suite of programs. The en-
tropy was computed for each snapshot from normal mode analyses
by using the Nmode program within the AMBER package.
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